Cited 13 times in
Salvage therapy with gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOX) for B-cell non-Hodgkin's lymphoma: a consortium for improving survival of lymphoma (CISL) trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김진석 | - |
dc.date.accessioned | 2018-11-23T11:33:02Z | - |
dc.date.available | 2018-11-23T11:33:02Z | - |
dc.date.issued | 2011 | - |
dc.identifier.issn | 0167-6997 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/165799 | - |
dc.description.abstract | BACKGROUND: We investigated response rates to and toxicities of gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOX) for the treatment of relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). PATIENTS AND METHODS: Patients with recurrent or refractory diffuse large B-cell lymphoma or mantle cell lymphoma (DLBCL) were eligible for enrollment in this study. Treatment consisted of gemcitabine 1,000 mg/m(2) intravenously (i.v.) on Days 1 and 8, ifosfamide 2,000 mg/m(2) i.v. on Day 1, dexamethasone 40 mg orally on Days 1-4, and oxaliplatin 130 mg/m(2) i.v. on Day 2, every 21 days. The primary goal of treatment was to establish a response rate after three cycles. Afterwards, patients could proceed to high-dose chemotherapy followed by autologous stem cell transplantation (HDC-ASCT) or receive up to six treatment cycles. RESULTS: Twenty-seven eligible patients were evaluated for toxicity and response. The median age of the patients was 54 years (range, 18-75 years), and most had DLBCL. After three cycles, there were four CR (15%) and 10 PR (37%) for an overall response rate (RR) of 52%. Among a total of 88 GIDOX cycles, grade 3 and 4 neutropenia occurred in 33% and 16% of the cycles, respectively. Likewise, grade 3 and 4 thrombocytopenia occurred in 14% and 16% of the cycles, respectively. Two patients (2%) experienced febrile neutropenia, while seven patients (26%) proceeded to HDC-ASCT. CONCLUSIONS: GIDOX is an active salvage regimen for aggressive B-cell NHL and can be tolerated by patients with acceptable toxicity | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Springer | - |
dc.relation.isPartOf | INVESTIGATIONAL NEW DRUGS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antineoplastic Agents/administration & dosage | - |
dc.subject.MESH | Antineoplastic Agents/adverse effects | - |
dc.subject.MESH | Antineoplastic Agents/therapeutic use | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/therapeutic use | - |
dc.subject.MESH | B-Lymphocytes/pathology* | - |
dc.subject.MESH | Deoxycytidine/administration & dosage | - |
dc.subject.MESH | Deoxycytidine/adverse effects | - |
dc.subject.MESH | Deoxycytidine/analogs & derivatives* | - |
dc.subject.MESH | Deoxycytidine/therapeutic use | - |
dc.subject.MESH | Dexamethasone/administration & dosage | - |
dc.subject.MESH | Dexamethasone/adverse effects | - |
dc.subject.MESH | Dexamethasone/therapeutic use* | - |
dc.subject.MESH | Disease-Free Survival | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Ifosfamide/administration & dosage | - |
dc.subject.MESH | Ifosfamide/adverse effects | - |
dc.subject.MESH | Ifosfamide/therapeutic use* | - |
dc.subject.MESH | Lymphoma, Non-Hodgkin/drug therapy* | - |
dc.subject.MESH | Lymphoma, Non-Hodgkin/pathology | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Organoplatinum Compounds/administration & dosage | - |
dc.subject.MESH | Organoplatinum Compounds/adverse effects | - |
dc.subject.MESH | Organoplatinum Compounds/therapeutic use* | - |
dc.subject.MESH | Salvage Therapy* | - |
dc.subject.MESH | Treatment Outcome | - |
dc.subject.MESH | Young Adult | - |
dc.title | Salvage therapy with gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOX) for B-cell non-Hodgkin's lymphoma: a consortium for improving survival of lymphoma (CISL) trial | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Byeong-Bae Park | - |
dc.contributor.googleauthor | Won Seog Kim | - |
dc.contributor.googleauthor | Hyeon Seok Eom | - |
dc.contributor.googleauthor | Jin Seok Kim | - |
dc.contributor.googleauthor | Young Yiul Lee | - |
dc.contributor.googleauthor | Suk Joong Oh | - |
dc.contributor.googleauthor | Dae Ho Lee | - |
dc.contributor.googleauthor | Cheolwon Suh | - |
dc.identifier.doi | 10.1007/s10637-009-9320-y | - |
dc.contributor.localId | A01017 | - |
dc.relation.journalcode | J01184 | - |
dc.identifier.eissn | 1573-0646 | - |
dc.identifier.pmid | 19756371 | - |
dc.identifier.url | https://link.springer.com/article/10.1007%2Fs10637-009-9320-y | - |
dc.subject.keyword | Gemcitabine | - |
dc.subject.keyword | Salvage therapy | - |
dc.subject.keyword | Non-Hodgkin’s lymphoma | - |
dc.contributor.alternativeName | Kim, Jin Seok | - |
dc.contributor.affiliatedAuthor | 김진석 | - |
dc.citation.volume | 29 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 154 | - |
dc.citation.endPage | 160 | - |
dc.identifier.bibliographicCitation | INVESTIGATIONAL NEW DRUGS, Vol.29(1) : 154-160, 2011 | - |
dc.identifier.rimsid | 60540 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.